이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Eris Lifesciences 관리
관리 기준 확인 4/4
현재 CEO에 대한 정보가 충분하지 않습니다.
주요 정보
Amit Bakshi
최고 경영자
₹48.8m
총 보상
| CEO 급여 비율 | 35.9% |
| CEO 임기 | 17.7yrs |
| CEO 소유권 | 42.9% |
| 경영진 평균 재임 기간 | 8yrs |
| 이사회 평균 재임 기간 | 3.9yrs |
최근 관리 업데이트
Recent updates
Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why
Sep 19
Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 27%
Sep 03Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
Aug 05Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Aug 04Estimating The Intrinsic Value Of Eris Lifesciences Limited (NSE:ERIS)
Jul 13Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
May 24Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price
May 10An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued
Mar 14Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report
Feb 15Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)
Dec 28Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly
Dec 07Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Nov 11Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?
Jul 20Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?
Nov 20These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely
Jun 20A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)
Feb 24Is Now The Time To Put Eris Lifesciences (NSE:ERIS) On Your Watchlist?
Dec 28Here's Why I Think Eris Lifesciences (NSE:ERIS) Might Deserve Your Attention Today
Sep 23If You Like EPS Growth Then Check Out Eris Lifesciences (NSE:ERIS) Before It's Too Late
May 26Eris Lifesciences Limited (NSE:ERIS) Shares Could Be 34% Above Their Intrinsic Value Estimate
Apr 17Eris Lifesciences Limited's (NSE:ERIS) Stock Has Fared Decently: Is the Market Following Strong Financials?
Mar 12Does Eris Lifesciences (NSE:ERIS) Deserve A Spot On Your Watchlist?
Feb 25Why Eris Lifesciences Limited (NSE:ERIS) Is A Dividend Rockstar
Feb 12Eris Lifesciences Limited (NSE:ERIS) Analysts Are Pretty Bullish On The Stock After Recent Results
Jan 30
Read This Before Buying Eris Lifesciences Limited (NSE:ERIS) Shares
Jan 17Our View On Eris Lifesciences' (NSE:ERIS) CEO Pay
Dec 30Is Eris Lifesciences Limited's (NSE:ERIS) Recent Performance Tethered To Its Attractive Financial Prospects?
Dec 10Eris Lifesciences (NSE:ERIS) Shareholders Booked A 25% Gain In The Last Year
Nov 23Is It Worth Buying Eris Lifesciences Limited (NSE:ERIS) For Its 1.1% Dividend Yield?
Oct 22CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | ₹4b |
| Mar 31 2024 | ₹49m | ₹17m | ₹4b |
| Dec 31 2023 | n/a | n/a | ₹4b |
| Sep 30 2023 | n/a | n/a | ₹4b |
| Jun 30 2023 | n/a | n/a | ₹4b |
| Mar 31 2023 | ₹49m | ₹17m | ₹4b |
| Dec 31 2022 | n/a | n/a | ₹4b |
| Sep 30 2022 | n/a | n/a | ₹4b |
| Jun 30 2022 | n/a | n/a | ₹4b |
| Mar 31 2022 | ₹46m | ₹26m | ₹4b |
| Dec 31 2021 | n/a | n/a | ₹4b |
| Sep 30 2021 | n/a | n/a | ₹4b |
| Jun 30 2021 | n/a | n/a | ₹4b |
| Mar 31 2021 | ₹27m | ₹27m | ₹4b |
| Dec 31 2020 | n/a | n/a | ₹3b |
| Sep 30 2020 | n/a | n/a | ₹3b |
| Jun 30 2020 | n/a | n/a | ₹3b |
| Mar 31 2020 | ₹49m | ₹18m | ₹3b |
| Dec 31 2019 | n/a | n/a | ₹3b |
| Sep 30 2019 | n/a | n/a | ₹3b |
| Jun 30 2019 | n/a | n/a | ₹3b |
| Mar 31 2019 | ₹49m | ₹18m | ₹3b |
| Dec 31 2018 | n/a | n/a | ₹3b |
| Sep 30 2018 | n/a | n/a | ₹3b |
| Jun 30 2018 | n/a | n/a | ₹3b |
| Mar 31 2018 | ₹49m | ₹11m | ₹3b |
보상 대 시장: Amit 의 총 보상 ($USD 581.61K )은 Indian 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 473.89K ).
보상과 수익: Amit 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Amit Bakshi (49 yo)
17.7yrs
테뉴어
₹48,776,648
보상
Mr. Amit Indubhushan Bakshi serves as Chairman and Managing Director at Eris Lifesciences Limited. Mr. Bakshi has an extensive experience of Indian Pharmaceutical industry and handles Strategic Management...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Chairman & MD | no data | ₹48.78m | 42.87% ₹ 74.0b | |
| Chief Financial Officer | 8yrs | ₹18.01m | 데이터 없음 | |
| Executive Director & COO | 3.3yrs | ₹44.85m | 데이터 없음 | |
| President of Sales & Marketing | no data | ₹22.05m | 데이터 없음 | |
| Executive Director | no data | ₹12.40m | 4.36% ₹ 7.5b | |
| Whole Time Director | no data | ₹6.99m | 3.28% ₹ 5.7b | |
| Senior Vice President | no data | ₹13.72m | 데이터 없음 | |
| Compliance Officer & Company Secretary | 8yrs | 데이터 없음 | 데이터 없음 | |
| President Medical | no data | ₹12.31m | 데이터 없음 | |
| Vice President | no data | ₹12.36m | 데이터 없음 | |
| Vice President | no data | ₹13.30m | 데이터 없음 | |
| Vice President | no data | ₹15.08m | 데이터 없음 |
8.0yrs
평균 재임 기간
50yo
평균 연령
경험이 풍부한 관리: ERIS 의 관리팀은 노련하고 경험 (평균 재직 기간 7.8 년)입니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Chairman & MD | 17.7yrs | ₹48.78m | 42.87% ₹ 74.0b | |
| Executive Director & COO | 3.8yrs | ₹44.85m | 데이터 없음 | |
| Executive Director | 17.7yrs | ₹12.40m | 4.36% ₹ 7.5b | |
| Whole Time Director | 4.1yrs | ₹6.99m | 3.28% ₹ 5.7b | |
| Independent Non-Executive Director | 6.4yrs | ₹4.13m | 데이터 없음 | |
| Independent Non-Executive Director | 2.2yrs | ₹4.05m | 데이터 없음 | |
| Independent Non-Executive Director | 3.7yrs | ₹4.51m | 데이터 없음 | |
| Independent Non-Executive Director | 3.8yrs | ₹4.65m | 데이터 없음 |
3.9yrs
평균 재임 기간
50yo
평균 연령
경험이 풍부한 이사회: ERIS 의 이사회는 경험(평균 재직 기간 3.7 년)으로 간주됩니다.